Search

Your search keyword '"M, Siciliano"' showing total 106 results

Search Constraints

Start Over You searched for: Author "M, Siciliano" Remove constraint Author: "M, Siciliano" Topic hepatology Remove constraint Topic: hepatology
106 results on '"M, Siciliano"'

Search Results

1. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

3. Multifactor risk evaluation in patients who have eradicated HCV infection: an interim analysis in the PITER cohort

4. P.09.10 CIRRHOTIC PATIENTS WITH MINIMAL HEPATIC ENCEPHALOPATHY PRESENT INCREASED CEREBRAL VASCULAR RESISTANCE, WHICH REMAINS UNCHANGED AFTER MEDICAL TREATMENT

5. Clinical impact of comorbidities in an Italian NAFLD cohort

6. Recipient perioperative cholesterolaemia and graft cholesterol metabolism gene expression predict liver transplant outcome

7. GENDER DIFFERENCES IN HCV CHRONIC LIVER DISEASE: A REAL LIFE EVALUATION IN PITER (PIATTAFORMA ITALIANA PER LO STUDIO DELLA TERAPIA DELLE EPATITI VIRALI) COHORT STUDY

8. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment

10. The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution

11. Clinical characterization and economic impact evaluation of anti-HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)

12. P.09.23 COMMON CLINICAL COMORBIDITIES IN AN ITALIAN NAFLD COHORT

13. P.09.30 NEW DIRECT-ACTING ANTIVIRAL (DAA) THERAPY IMPACTS LIVER STIFFNESS MEASUREMENTS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION

15. Nutritional status: its influence on the outcome of patients undergoing liver transplantation

16. The gut microbiota of cirrhotic patients with poor nutritional status: Preliminary evidences

17. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting

18. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

21. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies

22. P.09.13: Hepatoma Arterial-Embolisation Prognostic Score Predicts Progression in Hepatocellular Carcinoma Treated by Radiofrequency Ablation Plus Transarterial Chemoembolization

23. P.10.7: The GUT Liver Axis after Liver Transplantation: Modification of Intestinal Permeability and Correlation with Infectious Complications and Patients Prognosis

24. Natural HCV resistance is common in Italy and differently associated to genotypes

25. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

26. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network

27. Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study

28. Accuracy of a Point Shear Wave Elastography Technique (ElastPQ) in the Non-Invasive Assessment of Liver Fibrosis in a Large Cohort of Liver Patients

29. Failure to First-Line Direct Antiviral (DAA) Treatment of HCV Infection in an Italian Real-Life Urban Setting

30. Dynamic Contrast Enhanced Ultrasound Perfusion Imaging and Clinically Significant Portal Hypertension in Patients with Liver Cirrhosis: A Feasibility Study

31. P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS

32. P.16.8 ROLE OF TRANSCRANIAL DOPPLER (TCD) IN THE EVALUATION OF CEREBRAL HEMODYNAMIC IN CIRRHOTIC PATIENTS: CORRELATION WITH SEVERITY OF THE DISEASE AND MINIMAL HEPATIC ENCEPHALOPATHY (MHE) DEVELOPMENT

33. OC.04.3 PATIENT-TARGETED AND MULTIDISCIPLINARY MANAGEMENT IMPROVES SURVIVAL IN PATIENTS WITH HCC: THE HEPATOCATT EXPERIENCE

34. P.16.5 SAFETY AND EFFECTIVENESS OF PLASMA EXCHANGE IN SEVERE LIVER FAILURE

35. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein

36. ONE MONTH POST-OPERATIVE SERUM INSULIN PREDICTS SERUM AMINOTRANSFERASE ELEVATION AND FIBROSIS PROGRESSION DUE TO HCV RECURRENCE AFTER LIVER TRANSPLANTATION

37. Donor/recipient body surface area ratio as a novel predictor of graft survival after deceased donor liver transplantation

38. Older donor age is associated with increased donor oxidative stress and failure to restore basal total protein graft content after ischemia reperfusion injury in human liver transplantation

39. Early hepatocyte C4d expression and failure to restore basal hepatic total protein content after ischaemia–reperfusion are associated with 1-year graft loss in human liver transplantation

40. The anionic peptide fraction is present on the gallbladder apical epithelium and favours biliary cholesterol absorption

41. Graft HCV reinfection impairs the physiological increase of insulin hepatic extraction and pancreatic secretion rapidly occurring after liver transplantation

42. Preharvest donor hyperoxia predicts good early graft function and longer graft survival after liver transplantation

43. P.18.15 CONTRAST-ENHANCED ULTRASOUND EVALUATION OF TUMOR RESPONSE TO ANTI ANGIOGENETIC TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARINOMA

44. P.11.15 IMPACT OF PORTAL VEIN THROMBOSIS ON HEPATOCELLULAR CARCINOMA TREATMENT OUTCOME. THE HEPATOCAT GROUP EXPERIENCE

45. P.13.7 COMPARISON BETWEEN TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) AND TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH PERCUTANEOUS RADIOFREQUENCY ABLATION (TACE-RFA) FOR TREATMENT OF INTERMEDIATE HEPATOCELLULAR CARCINOMA (HCC)

46. F-29 Endothelial dysfunction in cirrhosis and its relationship with portal hypertension and liver failure

47. First post-transplant day ALT serum concentration predicts early hepatitis C recurrence after liver transplantation (LT)

48. 151 REDUCED DOSE AND DURATION OF SORAFENIB TREATMENT ARE ASSOCIATED TO TUMOR PROGRESSION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

49. 1042 SHORT-TERM EVALUATION OF HEPATOCELLULAR CARCINOMA AFTER SINGLE-STEP COMBINED TREATMENT: USEFULNESS OF CONTRAST-ENHANCED ULTRASONOGRAPHY

50. P.04.17 THE ROLE OF CONTRAST ENHANCED ULTRASOUND PERFUSION IMAGING AND DOPPLER INDICES IN THE NON-INVASIVE ASSESSEMENT OF LIVER FIBROSIS: A PRELIMINARY EXPERIENCE

Catalog

Books, media, physical & digital resources